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Abstract
Since the first demonstration of the protective effects of vaccinia inoculation, vaccination has been 
one of the medicine’s greatest successes. The design of vaccines against viral disease has evolved 
considerably over the last 50 years. Classically attenuated viruses, those created by passaging a 
virus in cultured cells, have proven to be an effective means for preventing many viral diseases, 
including smallpox, polio, measles, mumps, and yellow fever. However, empiric attenuation is not 
a reliable approach for all viruses and there are a number of safety issues associated with the use 
of live, attenuated viruses (LAVs). While inactivated viruses and subunit vaccines alleviate many 
of these concerns, they have generally been less efficacious than their LAV counterparts. 
Advances in molecular virology have provided new ways of controlling viral replication and 
virulence, renewing interest in LAV vaccines. These rationally attenuated viruses may lead to a 
new generation of safer, more widely applicable LAV vaccines. Here, we review several new 
approaches to viral attenuation and vaccine design, including deleterious gene mutation, altered 
replication fidelity, codon deoptimization, and control by microRNAs or zinc finger nucleases. 
While each of these approaches has garnered significant attention in recent months, they are still 
in their infancy and require further in vitro and animal testing before progressing to clinical trials.
Introduction
The basic goal of vaccination is to stimulate protective immunity while avoiding disease 
from the vaccine itself. The first generation of viral vaccines relied on empiric attenuation 
by repeated passage in cultured cells. Several live, attenuated viruses (LAVs) meet both 
criteria for vaccines; they elicit a strong and protective immune response with a low risk of 
disease from the vaccine itself. Despite recent successes in the development of LAV for 
rotavirus and several arboviruses, the classic attenuation process is somewhat unpredictable 
and has not always been applicable. In the present regulatory environment the use of LAVs 
has also been limited by safety concerns, including reversion to wild-type virulence. 
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Because LAVs are shed from vaccinees, they sometimes present a risk to unvaccinated 
individuals with impaired immunity.
These safety concerns have led to a shift toward the use of inactivated viruses or viral 
subunits as vaccines. Despite notable successes like the inactivated poliovirus vaccine 1, 
inactivated viruses are generally less immunogenic than their LAV counterparts, and this 
strategy is limited to viruses for which there are good culture and production systems. 
Subunit vaccines, which use viral proteins as immunogens, have become a major focus of 
vaccine development and have led to several successfully licensed vaccines, including 
vaccines against hepatitis B, influenza viruses, and papillomaviruses 2. Production is more 
easily controlled and efficient than that of LAVs or inactivated viruses. However, this 
strategy has not achieved universal success, as many subunit vaccines have failed to elicit a 
protective immune response in the host. While adjuvants have increased the immunogenicity 
of subunit vaccines, newer methods of subunit delivery mimic a natural immune response by 
incorporating more viral components. There are a number of approaches to this end 
including liposome delivery of antigens 3, 4, virus-like particles (VLPs) 5, and virosomes, 
which are reconstituted viral envelopes lacking any viral genetic material 6. Another 
approach to increase the immunogenicity of subunit vaccines is to recombinantly encode a 
pathogenic antigen in a non-pathogenic, yet infectious, poxvirus or adenovirus vector 7, 8. 
While there have been some notable successes, the major concern with this strategy is that 
the vector vaccines will not induce adequate immunological responses in hosts who have 
pre-existing antibodies against the vector.
A less live vaccine – rational attenuation through deletion or mutation
With this shift towards multi-subunit and vector designs, the vaccine field has accepted that 
more viral components are required for improved efficacy. As vaccines become more 
complex and “virus-like,” it is not surprising that live, attenuated vaccines have received a 
second look. Advances in molecular virology and the advent of recombinant virus systems 
have led to the identification of many viral genes associated with virulence and 
immunogenicity. Researchers have used this information to better control the replication and 
pathogenesis of vaccine candidates, thereby avoiding the unpredictability of empiric 
attenuation.
The identification of genes essential for viral replication and assembly led to the first 
generation of rationally designed, live virus vaccines (Table 1). Deletion or mutation of 
these genes results in a “defective virus,” which cannot replicate in the host (for an excellent 
review of defective virus vaccines, see Dudek and Knipe 8). These defective viruses are 
propagated in “helper” cells that express the missing gene(s). Though the virus is unable to 
replicate its genome, viral genes are still expressed, which can induce a strong immune 
response in the inoculated host. “Single cycle viruses,” which are defective in a viral protein 
required for assembly or spread, are a variation on this theme. While these viruses can 
replicate their genome through a single cycle, they do not produce infectious virus 9.
The first example of a replication-defective virus used as a vaccine was an HSV-1 strain 
with a deletion of a gene essential for genome replication 10. This virus stimulated an 
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immune response similar to natural infection and protected against wild-type virus challenge 
in a mouse model of infection 11. Replication-defective HSV-2 strains, which lack genes 
essential for viral DNA synthesis (UL5) and viral replication (UL29), have also been 
described 12. These viruses were more effective than subunit vaccines in eliciting protective 
immunity in mice 13 and did not establish latency 14, an important consideration in 
herpesviruses. HSV-1 and HSV-2 strains have also been created that lack glycoprotein H 
and are unable to spread from cell to cell or produce infectious progeny. These single-cycle 
viruses protect against wild-type challenge in rodent models 15, 16, but the block in viral 
spread may be leaky. Similar strategies are now being applied to viruses other than HSV. 
The newer smallpox vaccines are replication-defective viruses 8, and an influenza NS-2 
knockout and HA cleavage site mutants were shown to provide protective immunity in mice 
17, 18. Likewise, flaviviruses with a deletion in the C protein function as single-cycle 
viruses as they cannot spread between cells or encapsidate virus. These viruses can elicit a 
potent immune response and protect against wild-type challenge 19.
Even with progress in the attenuation of viruses by deleterious gene mutation, this approach 
has not led to a safe and effective vaccine for human disease. While this can be attributed to 
the relatively short time this field has been in existence, vaccines based on deleterious gene 
mutation often evoke only a weak immune response because the antigen is only expressed at 
the site of inoculation. There are also safety concerns about the completeness of the block in 
viral spread in single-cycle viruses 19. Like conventional LAVs, it has proven very difficult 
to balance immunogenicity with safety, even with the rational design of replication-
defective viruses. Over the last several years, investigators have taken advantage of recent 
advances in molecular virology and developed rational approaches to viral attenuation. In 
the following sections, we review four new methods - altered replication fidelity, codon 
deoptimization, and control by microRNAs or zinc finger nucleases. These novel LAV 
designs each allow for limited viral replication and antigen production. Because the host 
immune response is not required to limit viral spread, these LAVs may be safer than 
classical LAVs, even in immunocompromised patients.
Riboviral replication fidelity – failure then success
While LAV vaccines have been developed for many RNA viruses, the mutability of these 
pathogens presents unique challenges for vaccine design. The RNA-dependent RNA 
polymerases (RdRp) of RNA viruses exhibit characteristically low fidelity with measured 
mutation rates of 10−3 to 10−5 mutations per nucleotide copied per replication cycle 20. 
These mutation rates are orders of magnitude greater than those of nearly all DNA-based 
viruses and organisms. Because the genomes of RNA viruses are typically < 10,000 
nucleotides, this mutation rate translates to roughly 0.1–10 mutations per genome replicated. 
It has been estimated that every possible point mutation and many double mutations are 
generated with each viral replication cycle and may be present within the population at any 
time 21. This impressive diversity has important biological implications. First, low 
frequency variants within the population may contain, or quickly acquire, mutations in key 
epitopes, which mediate escape from vaccine-elicited neutralizing antibody or cytotoxic T 
cells 22. Antigenic drift within the hemagluttinin and neuraminidase proteins of influenza 
virus is the best example of this process and the primary reason for annual reevaluation of 
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vaccine strains 23. Second, many RNA viruses, including the human immunodeficiency 
virus (HIV) and hepatitis C virus (HCV), exhibit such dramatic intra- and interindividual 
genetic diversity, that it has been difficult to identify stable, conserved epitopes that provide 
universal protection against all strains 22. Finally, the mutability of RNA viruses has 
triggered real concerns about the potential reversion of live, attenuated vaccines to 
pathogenic strains. Both mutation and recombination are likely to play a role in this process, 
and the sporadic emergence of vaccine-derived polioviruses is a cautionary tale 24.
A large body of work in recent years suggests that because of their mutation rates, the 
evolution of RNA viruses may differ fundamentally from that of DNA-based organisms. 
Much of this work builds on the mathematical framework of quasispecies theory and seeks 
to understand the importance of genetic diversity at the population level 25. According to 
quasispecies theory, the mutation rates of RNA viruses place them near a critical “error 
threshold.” Below this threshold, the mutant spectrum within the population favors 
adaptability, and low fitness variants are tolerated so long as the majority remains viable. 
Beyond the error threshold, too many mutations accumulate, genetic information is lost, and 
the population becomes inviable 26. Indeed, mutagenic nucleosides increase viral mutation 
rate and cause population collapse, thus providing an effective treatment for several RNA 
viruses. However, several groups have identified mutants in poliovirus and foot and mouth 
disease virus (FMDV) that were resistant to nucleoside analogues 27–29. Further studies 
revealed that these variants replicated with higher fidelity by virtue of mutations within the 
viral RNA-dependent RNA polymerase. As a result, drug resistant mutants gave rise to 
populations with significantly less genetic diversity than wild type 30. Significantly, this 
decrease in diversity was responsible for attenuation in a transgenic mouse model of 
infection 30, 31.
We hypothesized that the observed attenuation of these high fidelity variants could be 
exploited for vaccine design 32. We focused on glycine 64 of the poliovirus polymerase, 
which regulates fidelity through a complex hydrogen bond network and mediates sensitivity 
to nucleoside analogues 27. Of the 19 possible amino acid substitutions at this position, only 
13 gave rise to viable virus, and 8 of these were unstable. The other 5 mutants had lower 
mutation rates than wild type and were less adaptable in cell culture. In the transgenic mouse 
model, these high fidelity variants were markedly attenuated and shed less efficiently than 
wild type. Three of the viruses stimulated high titers of neutralizing antibody in infected 
mice, an order of magnitude greater than the Sabin 1 vaccine strain. They also induced long-
lasting immunity. Mice vaccinated with G64S, G64A, or G64L survived a lethal challenge 
of wild type virus at 1 or 6 months via the intraperitoneal or intramuscular route.
This work suggests that controlling replication fidelity is a promising approach for 
engineering live, attenuated vaccines. However, several important questions remain. While 
it is clear that such a strategy could be successful for other picornaviruses, which have 
structurally conserved polymerases, it may be difficult to identify the relevant residues in 
other viral RdRp. In these cases, selection for nucleoside analogue resistance may be an 
unbiased way of discovering promising mutants for further characterization. Reversion to 
wild type is another potential problem, since viruses containing the lower fidelity wild type 
polymerase appear to have a selective advantage. Although high fidelity variants would 
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certainly revert at a lower frequency, their mutation rate is still significantly higher than that 
of DNA viruses 20, 30. We found no evidence for reversion of the G64S mutation after 
either twenty passages in HeLa cells or five mouse to mouse passages over twenty-five days 
32. While encouraging, further experiments along these lines will likely be required prior to 
regulatory approval. Finally, the mouse model for poliovirus pathogenesis is an imperfect 
one and the level of attenuation observed here may not reflect the situation in human 
vaccinees. Nevertheless, the high fidelity variants could still be useful in the ongoing polio 
eradication campaign, as safer seed strains will be needed for large scale production of the 
inactivated polio vaccine in a post-polio world 33.
Attenuation by a thousand cuts
It is well known that many organisms exhibit a codon bias, using some synonymous codons 
or codon pairs more frequently than others 34. In bacteria and simple eukaryotes, codon 
preference is related to levels of the corresponding tRNA and affects translational efficiency 
35, 36. The reasons for the observed codon bias are less clear in mammals. Because viruses 
rely on the host cell machinery for nearly all aspects of replication, it is not surprising that 
codon bias has been described in many viral genomes. In bacteriophage, codon usage 
closely mirrors that of the host 37. The bias is more pronounced in the highly expressed 
structural genes, suggesting optimization for translational efficiency 38, 39. Most 
mammalian viruses also have a strong preference against CpG dinucleotides, although their 
overall GC content is highly variable 38. Studies of HIV and influenza suggest that codons 
in highly variable surface proteins may be optimized for their volatility, the probability that 
a codon will mutate to a different amino acid class 40, 41. This would presumably facilitate 
immune escape and suggests that there has been selection for genetic plasticity in these 
highly mutable viruses.
Recent studies of poliovirus have addressed the importance of codon bias for viral 
replication and pathogenesis. Burns and colleagues performed large-scale mutagenesis of the 
Sabin 2 vaccine strain, replacing up to 50% of the capsid codons with synonymous codons 
that are less preferred in the human genome 42. While these codon-deoptimized viruses 
exhibited minimal defects in viral gene expression, they produced fewer infectious progeny 
and overall fitness was markedly reduced. A subsequent study found synonymous changes 
that increased the frequency of CpG and UpA dinucleotides had similar effects on viral 
fitness 43. Mueller and colleagues took a similar approach, but used gene synthesis 
technology to design poliovirus genomes with completely deoptimized codons in the capsid 
region 44. They also found a dramatic reduction in replicative fitness and a reduction in 
infectious progeny. However, their data strongly suggested that deoptimized viruses had 
reduced translational efficiency compared to wild type. They obtained similar results with 
viruses in which synonymous changes were determined by codon pair bias. In both cases, 
they found that deoptimized polioviruses were attenuated by 1000 fold on a per particle 
basis compared to wild type.
Because all changes are synonymous, the proteins expressed from codon-deoptimized 
viruses are identical to wild type and similarly immunogenic. Mueller and colleagues, 
therefore, hypothesized that their marked attenuation would make them ideal live vaccines 
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45. In their second study, they showed that deoptimized viruses provoked a robust 
neutralizing antibody response following three weekly intraperitoneal inoculations. All 
immunized mice survived subsequent lethal challenge with wild type poliovirus, 
demonstrating the vaccine efficacy of the engineered viruses. As a general strategy for 
vaccine development, codon deoptimization offers several advantages. First, attenuation 
does not affect antigenicity, and the immune response should closely mimic a natural 
infection. Second, because attenuation is systematic rather than empiric, it may be easily 
applied to other viruses. Finally, codon deoptimized viruses encode hundreds of point 
mutations, each with a fairly small individual effect on fitness. Consequently, there is little 
risk of reversion to virulence with even a handful of point mutations. Both Mueller and 
Burns found that codon deoptimized viruses are genetically stable and remain attenuated 
after repeated passage 42, 44. Their marked sequence divergence from circulating strains 
may also reduce the frequency of recombination and the risk of pathogenic, vaccine-derived 
variants.
Much work remains to be done before codon deoptimized viruses are employed as live, 
attenuated vaccines. While the results among the studies are consistent, the mechanism of 
attenuation is still debated. This would certainly be an issue for regulatory bodies, and the 
lack of clarity makes if difficult to determine whether codon-based attenuation is a unique 
aspect of picornaviruses, or a more generalizeable approach to vaccine design. As in the 
case of the high fidelity variants, the mouse model may not be the best system for assessing 
vaccine efficacy and safety. Nevertheless, codon deoptimization is a promising approach 
that has already generated significant interest in the virology community.
MicroRNA-controlled LAVs
Since the discovery of RNA interference (RNAi) just a decade ago, there has been an 
explosion of research into this novel form of gene regulation. The two main effectors of 
RNAi are small interfering RNA (siRNA) and microRNA (miRNA) 46. While there has 
been intense interest in using siRNAs to combat mammalian RNA viruses 47, miRNAs are 
now also being used to limit viral pathogenesis. MicroRNA are genomically encoded and 
play a major role in endogenous gene regulation 48. They are transcribed as long precursor 
pri-miRNA, which are processed by the nuclear ribonuclease Drosha to ~ 60 nucleotide 
hairpin intermediates, which are then transported to the cytoplasm where they are trimmed 
by Dicer to roughly ~ 22 nucleotides (Figure 1). Like siRNAs, mature miRNA are loaded 
into the RNA-induced silencing complex (RISC), where they mediate either degradation or 
translational repression of target messages. The human genome encodes over 400 miRNA, 
many of which have tissue-specific or developmental expression patterns. Several DNA 
viruses also express miRNA 49. These virally derived miRNA modulate pathogenesis and 
host immunity through regulation of viral and cellular transcripts, respectively.
The diversity and complexity of cellular miRNA means that many cell types will have a 
unique miRNA profile 50. Several investigators have taken advantage of this property to 
better target viral gene therapy vectors 51. Silencing of specific transcripts or the entire 
genome can be accomplished by inclusion of miRNA binding sites in the vector sequence. 
In many cases, the miRNA system is used to provide a second level of control beyond 
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receptor expression or tissue-specific promoter activity. For example, Brown and colleagues 
eliminated off-target expression from a hepatocyte specific promoter in antigen presenting 
cells by incorporating miR-142-3p binding sites in their lentiviral construct 52. In a related 
study, muscle-specific miRNA binding sites were used to limit secondary replication of a 
Coxsackie virus in a murine tumor model 53. Improved targeting of adenoviral vectors has 
also been achieved by the addition of miRNA binding sites to the 3’ untranslated region of 
the E1A transcript 54, 55.
In LAV design, empiric attenuation of viruses is often accomplished by changing the tissue 
tropism of a virus through repeated passage in a new cell type. We hypothesized that the 
same result could be achieved through miRNA restriction of poliovirus replication 56. While 
poliovirus replicates in many tissues, disease onset is linked to lytic infection of the central 
nervous system. By incorporating binding sites for either let7a (a ubiquitous miRNA) or 
miR124 (a CNS restricted miRNA) into the RNA genome of wild type poliovirus (Figure1), 
we showed that viral replication was restricted in a cell-type dependent manner and that the 
effect was dependent on the cellular RNAi machinery. The miRNA-targeted viruses were 
largely restricted from the central nervous system in a murine model of infection, and 
markedly attenuated as a result 56. Experiments with viruses containing mutant target 
sequences confirmed that the altered tropism was due to miRNA. The degree of attenuation 
exceeded 5 orders of magnitude and neither let7a- nor miR124-targeted viruses were 
pathogenic in immunocompromised mice lacking the alpha/beta interferon receptor 56. Both 
viruses were able to replicate in non-neuronal tissues and stimulated a strong neutralizing 
antibody response after a single intraperitoneal inoculation. The level of protection was 
impressive, as even the interferon receptor knockout mice were protected from subsequent 
challenge with 10,000 times the lethal dose of wild type virus 56.
While miRNA targeting is a promising approach to rational design of LAV, the study has 
several caveats worth mentioning. The let7a virus replicated poorly in most tissues, while 
the mir124 virus was restricted only in the central nervous system 56. As a result, the former 
stimulated a weaker immune response and was a less effective vaccine. On the other hand, 
widespread replication of the mir124 virus in non-neuronal tissues could allow the virus to 
accumulate mutations within the miRNA target sequence and thereby escape degradation. 
Indeed, several mice in the study had low titers of mir124 virus in the spinal cord, and 
sequence analysis showed mutations within the miRNA target sequences 56. Work from our 
laboratory suggests that a single let7a site can accumulate escape mutations in as little as 
24–48 hours 32. The risk of miRNA-escape could be minimized by the inclusion of multiple 
target sequences for the same miRNA or different miRNA with the same tissue distribution. 
Another way of minimizing escape was highlighted in a subsequent paper on species-
specific restriction of influenza virus for vaccine production 57. In this study, Perez and 
colleagues incorporated nonavian miRNA target sequences into a region of the viral 
nucleoprotein open reading frame. Because the miRNA target sequence also served as 
codons for conserved amino acids, escape mutations would alter protein structure and likely 
have a deleterious effect on viral replication. We expect that as the RNAi field matures, 
investigators will find other ways of controlling the replication and mutability of miRNA-
targeted vaccines, though the potential for reversion to wild type will have to be mitigated to 
the satisfication of regulatory bodies.
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Zinc finger nuclease-controlled LAVs
Zinc finger (ZF) domains mediate nucleotide-specific binding of proteins to DNA, a 
property that defines a large family of DNA binding proteins 58. Each finger makes contact 
with a separate DNA triplet, and natural or recombinant ZFs have been created that can 
recognize almost any triplet 59. The modular nature of the ZFs allows them to be joined in 
useful combinations. Typically, three ZFs are combined to bind to a specific 9-bp DNA 
sequence, and these ZFs have been coupled to various functional domains to create artificial 
transcription factors that can activate or repress gene transcription with remarkable promoter 
specificity 60. Zinc fingers have also been fused to the nuclease domain of the restriction 
enzyme FokI to cleave double-stranded DNA at specific sequences 61. The nuclease domain 
must dimerize to cleave DNA, and because the dimer interface is weak, two nuclease 
domains are typically brought into close proximity by pairs of ZFs binding to neighboring 9-
bp sites, spaced 6-bp apart (Figure 2) 62, 63. In this configuration, the engineered ZF 
nuclease (ZFN) recognizes a specific 18-bp sequence, which is long enough, by a few orders 
of magnitude, to be unique in the human genome. Because of this specificity, this same 
technology could be used to distinguish between human and virus DNA.
Several groups have used recombinant ZF proteins to control aspects of the viral life cycle. 
ZF proteins fused to the KOX-1 repression domain were created that targeted the HSV-1 
ICP4 promoter 64. These proteins bound the promoter with nanomolar affinity, and one was 
able to significantly repress VP16-activated transcription in vitro. This ZF-KOX-1 fusion, 
when delivered in trans into HSV-1 infected cells, was able to limit HSV-1 replication and 
reduced viral titer by 90%. In a similar strategy, recombinant ZF proteins were designed to 
recognize the HPV-18 replication origin 65. When expressed in vitro, these ZFs were able to 
compete with the replication protein E2 for binding to viral DNA. This competitive 
antagonism led to reduced HPV replication in transient replication assays in mammalian 
cells. By fusing the origin-targeted ZF protein to a nuclease domain this ZFN was able to 
cleave viral DNA and reduce viral replication in cultured cells 66. These experiments 
demonstrate that ZFN can effectively target and eliminate viral DNA in mammalian cells.
It may be feasible to deliver a therapeutic virus-specific ZFN in trans to eradicate latent viral 
DNA. However, delivery of the ZFNs to all latently infected cells is technically challenging. 
Alternatively, virus-specific ZFNs could be delivered using the viral genome itself and serve 
as a vaccine. In the ZFN-vaccine strategy, ZFNs targeting sequences for viral replication and 
other essential viral processes would be introduced into the viral genome (Figure 2). 
Following inoculation, immunogenic viral genes and virus-specific ZFNs would be 
expressed. While the viral proteins would stimulate a natural immune response, the ZFNs 
would cleave viral DNA, and limit replication. ZFN-LAVs have potential both as 
prophylactic vaccines, protecting against wild-type challenge, as well as therapeutic 
vaccines, delivering ZFNs to cells already harboring latent viral DNA.
The immunogenicity of ZFN vaccines can be controlled by temporal and spatial regulation 
of ZF expression to balance viral protein expression with the ability of the ZFNs to eliminate 
all replication-competent viral DNA. This could best be accomplished using promoters that 
are temporally controlled by the virus itself. For instance, herpesvirus gene transcription 
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occurs in at least three distinct stages; immediate-early (before most of viral protein 
synthesis), early (before viral replication), and late (after viral replication begins) 67. Other 
DNA viruses for which ZFNs would be useful are similarly regulated. There is also the 
potential to encode ZFNs behind inducible promoters, so that ZFN expression would 
commence upon the administration of a small molecule 68. Nuclease activity can also be 
controlled directly by addition of small molecule-sensitive residues to the ZFN 69. These 
strategies would provide an ideal way to optimize the balance between ZFN-virus 
replication and nuclease activity.
The ability to create a ZFN-vaccine that can prevent and eliminate persistent viral infections 
is a long way from being realized. As with any LAV, safety issues are always a concern. 
The ZFN vaccine approach would likely be limited to non-integrating, DNA viruses, as 
random breaks in host chromosomal DNA caused by ZFN-cleavage of integrated viral DNA 
could be catastrophic. There are many non-integrating human viruses, includes the herpes-, 
polyoma-, adeno-, and papillomaviruses, that establish a persistent infection and provide 
particularly difficult challenges for the treatment of their respective diseases. ZFN-based 
vaccines may offer a way to prevent or eliminate these hard-to-treat latent infections. 
Reversion to wild type is another concern, but the risk can be reduced by including ZFNs 
against multiple, essential viral sequences to ensure that the intrinsic mutation rate of the 
virus will not allow the mutation of every ZFN target site. It is also possible that DNA 
cleaved by ZFNs could be repaired via homologous recombination using uncleaved viral 
genomes. However, if the sequence were repaired accurately, it would be subject to repeated 
cleavage; if it is repaired inaccurately, the virus should not be viable due to mutation of an 
essential sequence. Ideally, we will arrive at a live virus strain that will have limited 
replication, not establish latency, and elicit a protective immune response. In essence, we 
would turn an otherwise detrimental latent infection into an asymptomatic, acute infection.
Conclusions
LAV vaccines have provided ideal protection from several major diseases, but have not 
lived up to their potential due to limited applicability and safety concerns. Advances in 
molecular biology have opened the door to novel approaches to viral attenuation and may 
lead to a new generation of safer LAVs (Table 2). Though replication-defective LAVs have 
encountered some problems, this approach to attenuation is on the cusp of providing safe, 
effective vaccines for several diseases. Several other approaches to attenuation are poised to 
overcome other problems specifically associated with vaccine design for RNA and DNA 
viruses. For many RNA viruses where high mutation rates limit the efficacy of vaccines, 
altering the replication fidelity can attenuate the entire virus population, leading to 
population collapse without mutation of key immunogenic epitopes. Codon deoptimization 
provides a systematic means by which to attenuate any virus. By substituting synonymous 
codons throughout a viral genome, there is no loss of immunogenicity and little risk of 
reversion to wild type. Zinc finger nucleases and miRNAs can be used to control the 
replication of DNA and RNA viruses, respectively. By controlling viral replication 
temporally or spatially, a strong, natural immune response can be elicited before the virus is 
eliminated. These may be particularly useful approaches for designing vaccines against 
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persistent or latent viruses, as ZFNs and miRNAs lead to the elimination of all viral DNA or 
RNA, thus preventing chronic infection.
Each of these approaches is aimed to address long-standing problems with LAV vaccine 
design. While they could potentially change the way we think about attenuation, significant 
hurdles lie ahead. Live vaccines present an inherent trade-off between safety and efficacy, 
and regulatory bodies are right to be concerned about viral escape or reversion to wild type. 
The studies described here have largely been carried out in murine models with relatively 
short-term measures of immunogenicity and limited characterization of viral genetic 
stability. Much more work is needed in relevant animal models before contemplating an 
initial dosing and safety trial in humans. We expect that each strategy will need to be 
modified to optimize its safety and efficacy profile. Nevertheless, the efficacy demonstrated 
by available LAV, particularly the recent success in developing safe and effective live-
attenuated rotavirus, influenza, and varicella zoster vaccines is a strong incentive to redouble 
efforts to improve the safety characteristics of this type of vaccine. Rational attenuation may 
also facilitate the development of inactivated vaccines for high-risk agents by providing 
safer seed stocks for large-scale production. The next several years will clearly be an 
exciting time in vaccine research as advances in molecular biology are further translated into 
preventive strategies for viral disease.
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Figure 1. miRNA-virus vaccine strategy
Genes coding for one or more microRNA are transcribed as long precursor pri-miRNA, 
which are processed by the nuclear ribonuclease Drosha to ~ 60 nucleotide hairpin 
intermediates. These small RNA are transported to the cytoplasm where they are trimmed by 
Dicer to roughly ~ 22 nucleotides. Mature miRNA are loaded into the RNA-induced 
silencing complex (RISC), where they mediate either degradation or translational repression 
of target messages. Viral replication can be regulated in a tissue specific manner by 
incorporating miRNA target sites into the viral genome. Viral RNA are cleaved in cells 
expressing the corresponding miRNA (e.g. brain, top cell), and viral production is restricted 
to cells in which the miRNA is not expressed (e.g. intestine, bottom cell). The engineered 
virus can therefore trigger a natural immune response in target tissues without the associated 
risk of dissemination and disease.
Lauring et al. Page 14
Nat Biotechnol. Author manuscript; available in PMC 2010 December 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. ZFN-virus vaccine strategy
Zinc finger nucleases use an array of three zinc finger (ZF) domains to recognize specific 
9bp sequences in the virus genome. The ZF array is fused to DNA nuclease domain 
(lightning bolt) to create the zinc finger nuclease (ZFN). This nuclease is only active upon 
dimerization. A pair of ZFNs can be designed to bind 9bp sequences, spaced 5–6bp apart, to 
bring the nuclease domains close enough to dimerize, thus cleaving the double-stranded 
DNA sequence. ZFNs can be designed that target multiple, essential viral sequences, such as 
the origin of replication, the viral DNA packaging signal, sequences essential for 
establishment and maintenance of latency, and genes essential for viral replication. These 
ZFNs can be encoded in the viral genome itself using recombinant techniques. The 
expression of the ZFNs can be temporally controlled using viral promoters to allow a 
balance between expression of immunogenic viral proteins and cleavage of circular 
episomal DNA to linear DNA. This linear DNA is incapable of replication and 
establishment of latency. Thus, a ZFN-virus vaccine can elicit an immune response equal to 
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that of the parental virus, but can limit its own replication and latency, without the need for a 
competent immune system.
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Table 1
Current Vaccine Strategies
Vaccine
Approach
Construction Safety
Empirically
attenuated virus
Blind passage in different cell types. By
adapting to a new environment, the
virus accumulates mutations that
mediate attenuation.
Host immunity is able to limit that
virulence and spread of the attenuated
virus
Inactivated virus Virus is inactivated by chemical
treatment (e.g. formaldehyde).
Disruption of viral proteins and/or
genetic material.
Subunit Vaccine Recombinant expression of one or
several viral proteins.
No viral genetic material is included.
Viral vectors One or several genes from a virus are
inserted into the genome of a second
nonpathogenic virus (the vector). Viral
particles produced by the vector
transduce these genes into target cells
and direct their expression.
The vector itself is attenuated (see
above), but is able to express antins
derived from the pathogenic virus.
Replication
Defective Viruses
One or several genes required for
genome replication are deleted in the
vaccine strain. The virus vaccine is
produced in a helper cell line that
expresses the missing protein(s) in
trans.
The administered virus is unable to
replicate its genome.
Single Cycle
Viruses
One or several genes required for viral
assembly and spread are deleted in the
vaccine strain. Distinguished from
replication defective viruses by their
competence for genome replication.
The virus is able to replicate its
genome, but is defective for assembly
or spread.
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Table 2
Approaches to viral attenuation for vaccine design
Vaccine
Approach
Advantages Disadvantages Examples
Empirically
attenuated virus
Excellent
immunogenicity, few
doses required
Limited applicability,
reversion to wild type,
breakthrough disease
Measles, mumps, rubella
(MMR); Oral polioirus
vaccine (OPV), Influenza,
Rotavirus, Yellow Fever,
Varicella
Subunit Vaccine Widely applicable, very
safe
Poor immunogenicity,
multiple doses usually
required
Hepatitis B virus, Human
papilloma virus
Viral vectors Good immunogenicity,
delivery of multiple
antigens
Neutralizing antibodies to
vector, possible safety
issues
Many examples
(experimental)
Defective
Viruses
Good immunogenicity,
known mechanism of
attenuation
Limited to inoculation site,
possible safety issues
HSV-1, HSV-2. Influenza
(experimental)
Replication
Fidelity
Strong immunogenicity,
known mechanism of
attenuation, not
susceptible to antigenic
shift/drift
RNA viruses only,
possible reversion to wild
type
Poliovirus (experimental)
Codon
deoptimization
Strong immunogenicity,
no reversion to wild type,
possibly applicable to
many viruses
Possible safety concerns Poliovirus (experimental)
miRNA-
controlled virus
Strong immunogenicity,
known mechanism of
attenuation, prevent
latent infection
Limited to some RNA
viruses
Poliovirus, adenovirus,
coxsackievirus, influenza
(experimental)
ZFN-controlled
virus
Strong immunogenicity,
known mechanism of
attenuation, prevent
latent infection
Limited to non-integrating
DNA viruses
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